Literature DB >> 7075643

Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.

B Hallengren, O R Nilsson, B E Karlberg, A Melander, L Tegler, E Wåhlin-Boll.   

Abstract

The kinetic profiles of oral methimazole 40 mg, propranolol 80 mg, metoprolol 100 mg and atenolol 100 mg were compared in hyperthyroid patients both during the hyper- and euthyroid states. for methimazole, neither the peak concentration (Cmax), the time to reach peak concentration (tmax), the elimination half-life (t 1/2) nor the area under the curve (AUC) value was affected by the hyperthyroid state. For propranolol and metoprolol, which undergo extensive presystemic clearance, the AUC values were lower (p less than 0.02) when the patients were hyperthyroid than when they had become euthyroid, but the t 1/2's were not significantly altered. For atenolol, there were no significant kinetic differences between the hyperthyroid and euthyroid states. The findings are compatible with the assumption that hyperthyroidism does not affect the kinetics of methimazole or atenolol, but that it may enhance presystemic clearance of propranolol and metoprolol.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7075643     DOI: 10.1007/bf00542322

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

Review 1.  DRUG TOXICITY AS A RESULT OF INTERFERENCE WITH PHYSIOLOGICAL CONTROL MECHANISMS.

Authors:  J R GILLETTE
Journal:  Ann N Y Acad Sci       Date:  1965-03-12       Impact factor: 5.691

2.  Measurement of thyroxine by competitive protein binding.

Authors:  H Seligson; D Seligson
Journal:  Clin Chim Acta       Date:  1972-04       Impact factor: 3.786

3.  Effect of hyperthyroidism and hypothyroidism on the metabolism of testosterone and androstenedione in man.

Authors:  G G Gordon; A L Southren; S Tochimoto; J J Rand; J Olivo
Journal:  J Clin Endocrinol Metab       Date:  1969-02       Impact factor: 5.958

4.  Comparative In Vitro Effects and In Vivo Kinetics of Antithyroid Drugs.

Authors:  A Melander; B Hallengren; S Rosendal-Helgesen; A K Sjöberg; E Wählin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

5.  Radioimmunoassay for triiodothyronine (T 3 ): I. Affinity and specificity of the antibody for T 3 .

Authors:  H Gharib; R J Ryan; W E Mayberry; T Hockert
Journal:  J Clin Endocrinol Metab       Date:  1971-09       Impact factor: 5.958

6.  Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.

Authors:  E S Vesell; J R Shapiro; T Passananti; H Jorgensen; C A Shively
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

Review 7.  Drug metabolism in thyroid disease.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

8.  The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.

Authors:  G G Skellern; B I Knight; C K Low; W D Alexander; D G McLarty; W J Kalk
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

9.  Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.

Authors:  O R Nilsson; A Melander; L Tegler
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

10.  Effects of thyroid dysfunction on propranolol kinetics.

Authors:  J G Riddell; J D Neill; J G Kelly; D G McDevitt
Journal:  Clin Pharmacol Ther       Date:  1980-11       Impact factor: 6.875

View more
  9 in total

Review 1.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

5.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

6.  Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages.

Authors:  M Messina; P Milani; L Gentile; A Monaco; C Brossa; M Porta; F Camanni
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

Review 7.  Pharmacokinetics of long acting propranolol. Implications for therapeutic use.

Authors:  G S Nace; A J Wood
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

Review 8.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

Review 9.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.